PP 001 - Primary Peptides
Alternative Names: PP-001; SIM-0339; SIM-339Latest Information Update: 28 May 2024
At a glance
- Originator Primary Peptides
- Developer Primary Peptides; Simcere Pharmaceutical Group
- Class Peptides; Small molecules; Vascular disorder therapies
- Mechanism of Action Death-associated protein kinase inhibitors; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Stroke in Canada
- 06 Sep 2021 Preclinical trials in ishemic Stroke in China (unspecified route) , Simcere Pharmaceutical Group company pipeline September 2021)
- 06 Sep 2021 Simcere Pharmaceutical Group plans a phase I trial in ischemic Stroke in China